Antibacterial activity of quinupristin/dalfopristin: Rationale for clinical use

Drugs

Volumn 51, Issue SUPPL. 1, 1996, Pages 31-37

  Finch, Roger G ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; METICILLIN; PENICILLIN G; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; CLOSTRIDIUM PERFRINGENS; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; EXPERIMENTAL INFECTION; HAEMOPHILUS INFLUENZAE TYPE A; HEMOLYTIC STREPTOCOCCUS; HUMAN; LACTOBACILLUS; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; PEPTOSTREPTOCOCCUS; POSTANTIBIOTIC EFFECT; PSEUDOMONAS AERUGINOSA; RAT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; VIRGINIAMYCIN;

EID: 0030004654     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600511-00007     Document Type: Article

References (41)

1. Fass RJ. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 1991; 35: 553-9
2. Neu HC, Chin N, Gu J. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J Antimicrob Chemother 1992; 30 Suppl. A: 83-94
3. Archer GL, Doern GV, Fuchs PC, et al. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis 1993; 16: 223-6
4. Andrews JM, Wise R. The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens. J Antimicrob Chemother 1994; 33: 849-53
5. Hoban DJ, Weshnoweski B, Palatnick L, et al. In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. J Antimicrob Chemother 1992; 30 Suppl. A: 59-65
6. Verbist L, Verhaegen J. Comparative in-vitro activity of RP 59500. J Antimicrob Chemother 1992; 30 Suppl. A: 39-44
7. Goto S, Miyazaki S, Kaneko Y. The in-vitro activity of RP 59500 against Gram-positive cocci. J Antimicrob Chemother 1992; 30 Suppl. A: 25-8
8. Inoue M, Okamoto R, Okubo T, et al. Comparative in-vitro activity of RP 59500 against clinical bacterial isolates. J Antimicrob Chemother 1992; 30 Suppl. A: 45-51
9. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents, including RP 59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993; 32: 223-31
10. Nord CE, Lindmark A, Persson I. Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro. Eur J Clin Microbiol Infect Dis 1989; 8 (12): 1064-7
11. Aldridge KE, Schiro DD, Varner LM. In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrob Agents Chemother 1992; 36: 854-5
12. Scriver SR, Tyrrell G, Willey BM, et al. In vitro assessment of RP 59500 (RP) against vancomycin-resistant enterococci [abstract]. 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans: 312
13. Leclercq R, Nantas L, Soussy C-J, et al. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother 1992; 30 Suppl. A: 67-75
14. Fremaux A, Sissia G, Cohen R, et al. In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae. J Antimicrob Chemother 1992; 30 Suppl. A: 19-23
15. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, Win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1992; 36: 856-9
16. Johnson CC, Slavoski L, Schwartz M, et al. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis 1995; 21: 169-73
17. Barry AL, Fuchs PC. In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother 1995; 39: 238-40
18. Tarasi A, Tomasz A. Activity of RP59500 against multidrug resistant clones of Streptococcus pneumoniae [abstract no. E116]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, California: 106
19. Collins LA, Malanoski GJ, Eliopoulos GM, et al. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant Gram-positive organisms. Antimicrob Agents Chemother 1993; 37: 598-601
20. Freeman C, Robinson A, Cooper B, et al. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 1995; 21: 47-50
21. Scriver SR, Willey BM, Matsumara S. Susceptibility of glycopeptide-resistant enterococci including variant species to RP 59500 [abstract no. 13]. 2nd International Conference on Macrolides, Azalides and Streptogramins. 1994 Jan 19-21; Venice: 13
22. Casewell MW, Seyed-Akhavani M, Wade J. In-vitro activity of RP 59500 against vancomycin-resistant Enterococcus faecium also resistant to > 512 mg/L of gentamicin [abstract]. 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans: 313
23. Mahayni R, Perri MB, Dembry LM, et al. Comparative in-vitro and bactericidal activity of RP59500 (quinupristin/ dalfopristin), against multi-drug resistant E. faecium [abstract]. 34th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1994 Oct; Orlando: 27
24. Goldsmith MF. New forms and new needs may make macrolides antibiotics of the decade. JAMA 1992; 267(7): 903-4
25. Lorian V, Fernandes F. Synergistic activity of injectable streptogramin RP59500-vancomycin combination [abstract no. E126]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, California: 107
26. Kang SL, Rybak MJ. In vitro bactericidal activity of RP59500 (quinupristin/dalfopristin; RP) alone and in various combinations against resistant strains of Enterococcus species and Staphylococcus aureus (SA) [abstract no. E121]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, California: 107
27. Pankuch GA, Jacobs MR, Appelbaum PC. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother 1994; 38: 2065-72
28. Berthaud N, Charles Y, Gouin A-M, et al. In vitro bactericidal activity of RP59500 (quinupristin/dalfopristin) against adherent Staphylococcus aureus [abstract no. E122]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, California: 107
29. Desnottes JF, Diallo N. RP 59500: In vitro anti-staphylococcal bactericidal activity across platelet-fibrin matrices compared to that of vancomycin [abstract]. 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans: 259
30. Kang SL, Rybak MJ. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Antimicrob Agents Chemother 1995; 39: 1505-11
31. Johnson CC, Slavoski L, Schwartz M, et al. In vitro bactericidal activity of RP 59500 (Synercid) against antibiotic resistant strains of Streptococcus pneumoniae and Enterococcus spp. [abstract]. 34th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1994 Oct; Orlando: 28
32. Hill RLR, Smith C, Casewell M. Bactericidal and inhibitory activity of RP 50500 (quinupristin/dalfopristin) and its components against vancomycin- and gentamicin-resistant Enterococcus faecium [abstract no. E118]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, California
33. Boswell FJ, Andrews JM, Wise R. The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. J Antimicrob Chemother 1994; 33: 1219-22
34. Chin NX, Neu HC. Post-antibiotic effect of the new streptogramin RP 59500. Eur J Clin Microbiol Infect Dis 1992; 11: 642-5
35. Nougayrede A, Berthaud N, Bouanchaud DH. Post-antibiotic effects of RP 59500 with Staphylococcus aureus. J Antimicrob Chemother 1992; 30 Suppl. A: 101-6
36. Fantin B, Leclercq R, Ottaviani M, et al. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother 1994; 38: 432-7
37. Chambers HF. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1992; 30 Suppl. A: 117-22
38. Craig W, Ebert S. Pharmacodynamic activities of RP 59500 in an animal infection model [abstract]. 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans: 205
39. L'Hériteau F, Entenza JM, Lacassin F, et al. RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci. Antimicrob Agents Chemother 1995; 39: 1425-9
40. Berthaud N, Montay G, Huet Y, et al. RP 59500, in vitro bactericidal activity in a model of S. aureus mouse infection: influence of varying dosage and the number of treatments. Proceedings of the 32nd Interscience Conference of Antimicrobial Agents and Chemotherapy; 1992 Oct; Anaheim: 69-71
41. Berthaud N, Montay G, Conard BJ, et al. Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia. J Antimicrob Chemother 1995; 36: 365-73